Topics

Articles

Growth of CDMO's Pennsylvania facility will feature increase in cold chain storage capacity

Acquisition expands high-potent capabilities, along with oral development and manufacturing capacity

Division will operate under SCHOTT Pharma AG & Co. KGaA

CDMO’s new project focuses on addressing needs in oncology sector

Center will feature a $1.4 billion investment plan

Production capacity for the contract manufacturer is expected to more than triple

Will benefit CDMO’s Denmark and Texas locations

With a cost of approximately $514 million, expected completion is 2026

Cheshire facility will offer plasmid DNA production, CGT development